CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand [...]
